Copyright
©The Author(s) 2025.
World J Gastrointest Pharmacol Ther. Mar 5, 2025; 16(1): 103898
Published online Mar 5, 2025. doi: 10.4292/wjgpt.v16.i1.103898
Published online Mar 5, 2025. doi: 10.4292/wjgpt.v16.i1.103898
Table 1 Baseline characteristics
| Variables | mean ± SD |
| Age (years) | 44.94 ± 10.38 |
| Body mass index (kg/m2) | 25.43 ± 3.79 |
| Number of moderate heartburn episodes | 7 ± 6.3 |
| Number of severe heartburn episodes | 2.91 ± 3.3 |
| Duration of Happi ER treatment (weeks) | 4.6 ± 1.71 |
- Citation: Lawate P, Chauhan V, Prasad LR, Pawar A, Puranik AG, Bansal A, Koganti A, Jaiswal A, Puradkar P, Jhaveri K. Real-world-evidence, prospective-observational study to evaluate safety and effectiveness of rabeprazole dual-delayed-release capsules in patients with gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther 2025; 16(1): 103898
- URL: https://www.wjgnet.com/2150-5349/full/v16/i1/103898.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v16.i1.103898